Abstract: Described herein are compounds, or pharmaceutically acceptable salts thereof, of the following formula: The compounds are useful for treating inflammatory and autoimmune diseases.

Abstract: Described herein are compounds, or pharmaceutically acceptable salts thereof, of the following formula: The compounds are useful for treating inflammatory and autoimmune diseases.

Abstract: The techniques disclosed herein improve the efficiency of a system by providing intelligent management of content that is associated with objects displayed within communication sessions. The participants can generate a content object associated with a 3D object. The content object may be in the form of 3D virtual object such as an arrow pointing to the table, a text box of an annotation, etc. The content object may also include functional features that collect and display information voting agent. The system can generate a data structure that associates the object with the content object. The data structure enables a system to maintain an association between the object and the content object when various operations are applied to either object. Thus, if a remote computer sends a request for the content object, the associated object is delivered with the content object.

Abstract: A software application on a device controls a notification state of a peripheral device having a microphone, speaker and at least one button. The notification state includes one or more button press expression definitions and corresponding functions executable by the computing device. In response to receiving a sequence of button presses that satisfy a button press expression definition, the peripheral device sends a notification response causing the computing device to perform the corresponding action. The corresponding action may activate a voice assistant and make the voice assistant accessible through the peripheral device, which has fewer compute resources than are required to operate a voice assistance. In another example, the button press expression definitions can be used to control the mode in which a user enters a communication session, mute on, audio only, etc.

Abstract: A speakerphone and a computing device executing a voice over internet protocol (VoIP) communication application that provides communication session connectivity coupled via a direct communication channel provided by a wireless or wireline interconnection. The speakerphone and the VoIP communication application are configured with a messaging technology. The messaging technology allows the speakerphone and the VoIP communication application to exchange data, such as function data and information data.

Abstract: The techniques disclosed herein improve the efficiency of a system by providing intelligent management of content that is associated with objects displayed within communication sessions. The participants can generate a content object associated with a 3D object. The content object may be in the form of 3D virtual object such as an arrow pointing to the table, a text box of an annotation, etc. The content object may also include functional features that collect and display information voting agent. The system can generate a data structure that associates the object with the content object. The data structure enables a system to maintain an association between the object and the content object when various operations are applied to either object. Thus, if a remote computer sends a request for the content object, the associated object is delivered with the content object.

Abstract: Described herein are compounds, or pharmaceutically acceptable salts thereof, of the following formula: The compounds are useful for treating inflammatory and autoimmune diseases.

Abstract: This invention is directed to a compound of Formula I or a pharmaceutically acceptable salt thereof, wherein R1, R2, R3, R4 and X are as defined herein. The compounds of Formula I are useful as receptor tyrosine kinase (RTK) inhibitors and can be used to treat such diseases as cancer, blood vessel proliferative disorders, fibrotic disorders, mesangial cell proliferative disorders and metabolic diseases.

Abstract: This invention is directed to a compound of Formula I or a pharmaceutically acceptable salt thereof, wherein R1, R2, R3, R4 and X are as defined herein. The compounds of Formula I are useful as receptor tyrosine kinase (RTK) inhibitors and can be used to treat such diseases as cancer, blood vessel proliferative disorders, fibrotic disorders, mesangial cell proliferative disorders and metabolic diseases.

Abstract: This invention is directed to a compound of Formula I or a pharmaceutically acceptable salt thereof, wherein R1, R2, R3, R4 and X are as defined herein. The compounds of Formula I are useful as receptor tyrosine kinase (RTK) inhibitors and can be used to treat such diseases as cancer, blood vessel proliferative disorders, fibrotic disorders, mesangial cell proliferative disorders and metabolic diseases.

Abstract: This invention is directed to a compound of Formula I or a pharmaceutically acceptable salt thereof, wherein R1, R2, R3, R4 and X are as defined herein. The compounds of Formula I are useful as receptor tyrosine kinase (RTK) inhibitors and can be used to treat such diseases as cancer, blood vessel proliferative disorders, fibrotic disorders, mesangial cell proliferative disorders and metabolic diseases.

Abstract: This invention is directed to a compound of Formula I or a pharmaceutically acceptable salt thereof, wherein R1, R2, R3, R4 and X are as defined herein. The compounds of Formula I are useful as receptor tyrosine kinase (RTK) inhibitors and can be used to treat such diseases as cancer, blood vessel proliferative disorders, fibrotic disorders, mesangial cell proliferative disorders and metabolic diseases.

Abstract: This invention is directed to a compound of Formula I or a pharmaceutically acceptable salt thereof, wherein R1, R2, R3, R4 and X are as defined herein. The compounds of Formula I are useful as receptor tyrosine kinase (RTK) inhibitors and can be used to treat such diseases as cancer, blood vessel proliferative disorders, fibrotic disorders, mesangial cell proliferative disorders and metabolic diseases.

Abstract: This invention is directed to a compound of Formula I or a pharmaceutically acceptable salt thereof, wherein X, R1, R2, R3, R4, R5, R6 and R7 are as defined herein. The compounds of Formula I are useful as protein kinase (PK) inhibitors and can be used to treat such diseases as cancer, blood vessel proliferative disorders, fibrotic disorders, mesangial cell proliferative disorders, metabolic diseases inflammatory disorders and neurodegenerative disorders.

Abstract: This invention is directed to a compound of Formula I or a pharmaceutically acceptable salt thereof, wherein X, R1, R2, R3, R4, R5, R6 and R7 are as defined herein. The compounds of Formula I are useful as protein kinase (PK) inhibitors and can be used to treat such diseases as cancer, blood vessel proliferative disorders, fibrotic disorders, mesangial cell proliferative disorders, metabolic diseases inflammatory disorders and neurodegenerative disorders.

Abstract: Disclosed herein are methods of screening compounds that modulate G-protein coupled receptors. The assays are performed at temperatures of between about 25° C. and 40° C.